Hospital-Treated Gram-Negative Infections Market, Global Outlook and Forecast 2023-2029

Report ID: MMG251384 | Category: Medical Care | Pages: 61 | Format: PDF | Published Date: October 26,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials.
This report aims to provide a comprehensive presentation of the global market for Hospital-Treated Gram-Negative Infections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Treated Gram-Negative Infections. This report contains market size and forecasts of Hospital-Treated Gram-Negative Infections in global, including the following market information:
Global Hospital-Treated Gram-Negative Infections Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hospital-Treated Gram-Negative Infections market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Klebsiella Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hospital-Treated Gram-Negative Infections include Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals, Istituto lusofarmaco d’italia, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd and Alcon Laboratories, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hospital-Treated Gram-Negative Infections companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hospital-Treated Gram-Negative Infections Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Type, 2022 (%)
    Klebsiella
    Acinetobacter
    Coli
    Cepacia
    Pseudomonas
    Serratia
    Enterobacter
    Others
Global Hospital-Treated Gram-Negative Infections Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Application, 2022 (%)
    Public Hospital
    Private Hospital
Global Hospital-Treated Gram-Negative Infections Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hospital-Treated Gram-Negative Infections revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hospital-Treated Gram-Negative Infections revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Merck
    Pfizer
    AstraZeneca
    Abbott
    Lupin Pharmaceuticals
    Istituto lusofarmaco d’italia
    Adelco S.A
    Zhejiang yuntao biotechnology co., Ltd
    Alcon Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hospital-Treated Gram-Negative Infections, market overview.
Chapter 2: Global Hospital-Treated Gram-Negative Infections market size in revenue.
Chapter 3: Detailed analysis of Hospital-Treated Gram-Negative Infections company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hospital-Treated Gram-Negative Infections in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Hospital-Treated Gram-Negative Infections Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Hospital-Treated Gram-Negative Infections Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Hospital-Treated Gram-Negative Infections Overall Market Size
    2.1 Global Hospital-Treated Gram-Negative Infections Market Size: 2022 VS 2029
    2.2 Global Hospital-Treated Gram-Negative Infections Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Hospital-Treated Gram-Negative Infections Players in Global Market
    3.2 Top Global Hospital-Treated Gram-Negative Infections Companies Ranked by Revenue
    3.3 Global Hospital-Treated Gram-Negative Infections Revenue by Companies
    3.4 Top 3 and Top 5 Hospital-Treated Gram-Negative Infections Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Hospital-Treated Gram-Negative Infections Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Players in Global Market
        3.6.1 List of Global Tier 1 Hospital-Treated Gram-Negative Infections Companies
        3.6.2 List of Global Tier 2 and Tier 3 Hospital-Treated Gram-Negative Infections Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Hospital-Treated Gram-Negative Infections Market Size Markets, 2022 & 2029
        4.1.2 Klebsiella
        4.1.3 Acinetobacter
        4.1.4 Coli
        4.1.5 Cepacia
        4.1.6 Pseudomonas
        4.1.7 Serratia
        4.1.8 Enterobacter
        4.1.9 Others
    4.2 By Type - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts
        4.2.1 By Type - Global Hospital-Treated Gram-Negative Infections Revenue, 2018-2023
        4.2.2 By Type - Global Hospital-Treated Gram-Negative Infections Revenue, 2024-2029
        4.2.3 By Type - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Hospital-Treated Gram-Negative Infections Market Size, 2022 & 2029
        5.1.2 Public Hospital
        5.1.3 Private Hospital
    5.2 By Application - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts
        5.2.1 By Application - Global Hospital-Treated Gram-Negative Infections Revenue, 2018-2023
        5.2.2 By Application - Global Hospital-Treated Gram-Negative Infections Revenue, 2024-2029
        5.2.3 By Application - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Hospital-Treated Gram-Negative Infections Market Size, 2022 & 2029
    6.2 By Region - Global Hospital-Treated Gram-Negative Infections Revenue & Forecasts
        6.2.1 By Region - Global Hospital-Treated Gram-Negative Infections Revenue, 2018-2023
        6.2.2 By Region - Global Hospital-Treated Gram-Negative Infections Revenue, 2024-2029
        6.2.3 By Region - Global Hospital-Treated Gram-Negative Infections Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Hospital-Treated Gram-Negative Infections Revenue, 2018-2029
        6.3.2 US Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.3.3 Canada Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.3.4 Mexico Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Hospital-Treated Gram-Negative Infections Revenue, 2018-2029
        6.4.2 Germany Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.4.3 France Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.4.4 U.K. Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.4.5 Italy Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.4.6 Russia Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.4.7 Nordic Countries Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.4.8 Benelux Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Hospital-Treated Gram-Negative Infections Revenue, 2018-2029
        6.5.2 China Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.5.3 Japan Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.5.4 South Korea Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.5.5 Southeast Asia Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.5.6 India Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Hospital-Treated Gram-Negative Infections Revenue, 2018-2029
        6.6.2 Brazil Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.6.3 Argentina Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Hospital-Treated Gram-Negative Infections Revenue, 2018-2029
        6.7.2 Turkey Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.7.3 Israel Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.7.4 Saudi Arabia Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
        6.7.5 UAE Hospital-Treated Gram-Negative Infections Market Size, 2018-2029
7 Hospital-Treated Gram-Negative Infections Companies Profiles
    7.1 Merck
        7.1.1 Merck Company Summary
        7.1.2 Merck Business Overview
        7.1.3 Merck Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.1.4 Merck Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.1.5 Merck Key News & Latest Developments
    7.2 Pfizer
        7.2.1 Pfizer Company Summary
        7.2.2 Pfizer Business Overview
        7.2.3 Pfizer Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.2.4 Pfizer Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.2.5 Pfizer Key News & Latest Developments
    7.3 AstraZeneca
        7.3.1 AstraZeneca Company Summary
        7.3.2 AstraZeneca Business Overview
        7.3.3 AstraZeneca Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.3.4 AstraZeneca Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.3.5 AstraZeneca Key News & Latest Developments
    7.4 Abbott
        7.4.1 Abbott Company Summary
        7.4.2 Abbott Business Overview
        7.4.3 Abbott Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.4.4 Abbott Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.4.5 Abbott Key News & Latest Developments
    7.5 Lupin Pharmaceuticals
        7.5.1 Lupin Pharmaceuticals Company Summary
        7.5.2 Lupin Pharmaceuticals Business Overview
        7.5.3 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.5.4 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.5.5 Lupin Pharmaceuticals Key News & Latest Developments
    7.6 Istituto lusofarmaco d’italia
        7.6.1 Istituto lusofarmaco d’italia Company Summary
        7.6.2 Istituto lusofarmaco d’italia Business Overview
        7.6.3 Istituto lusofarmaco d’italia Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.6.4 Istituto lusofarmaco d’italia Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.6.5 Istituto lusofarmaco d’italia Key News & Latest Developments
    7.7 Adelco S.A
        7.7.1 Adelco S.A Company Summary
        7.7.2 Adelco S.A Business Overview
        7.7.3 Adelco S.A Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.7.4 Adelco S.A Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.7.5 Adelco S.A Key News & Latest Developments
    7.8 Zhejiang yuntao biotechnology co., Ltd
        7.8.1 Zhejiang yuntao biotechnology co., Ltd Company Summary
        7.8.2 Zhejiang yuntao biotechnology co., Ltd Business Overview
        7.8.3 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.8.4 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.8.5 Zhejiang yuntao biotechnology co., Ltd Key News & Latest Developments
    7.9 Alcon Laboratories
        7.9.1 Alcon Laboratories Company Summary
        7.9.2 Alcon Laboratories Business Overview
        7.9.3 Alcon Laboratories Hospital-Treated Gram-Negative Infections Major Product Offerings
        7.9.4 Alcon Laboratories Hospital-Treated Gram-Negative Infections Revenue in Global Market (2018-2023)
        7.9.5 Alcon Laboratories Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Hospital-Treated Gram-Negative Infections Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?